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Resumo 
 
Doenças cardiovasculares, biomarcadores, troponina cardiaca, 
ensaio de alta sensibilidade, Singulex Clarity System. 
 
 
As doenças cardiovasculares são a maior causa de morte em 
todo o mundo. A doença arterial coronária constitui uma das mais 
importantes, resultando em infarte agudo do miocárdio. 
Os biomarcadores cardiovasculares desempenham um papel 
fundamental na avaliação dos pacientes com dor torácica que dão 
entrada nas urgências. As troponinas cardíacas demonstraram 
uma alta sensibilidade e especificidade quase absoluta para o 
tecido do miocárdio. São considerados os biomarcadores padrão 
para a detecção de lesão do miocárdio. 
A introdução do ensaio de troponina de alta sensibilidade 
permite medir concentrações abaixo dos níveis convencionais de 
detecção e revelou um espectro de troponina cardíaca circulante 
em indivíduos saudáveis.  
A fim de avaliar o desempenho analítico e clínico de um ensaio 
de troponina sensível, com o intuito de auxiliar no rastreio ou na 
detecção precoce de doenças cardiovasculares, foram realizados 
vários ensaios em pacientes (um estudo percentual normal, um 
estudo de precisão, um estudo de linearidade, um estudo de 
comparação de pacientes e um estudo de estabilidade). 
Todas as amostras foram testadas entre o laboratório de rotina 
e o laboratório de Investigação no Hospital St George’s NHS 
Foundation Trust em Londres, de acordo com os princípios éticos.  
O presente estudo permitiu confirmar a sensibilidade deste 
novo ensaio de troponina cardíaca I e provou que o Singulex Clarity 
System é um aparelho com potencialidades na óptica de 
desempenho analítico. No entanto, devido ao seu longo tempo de 
manutenção, de avaliação dos controlos de qualidade e por ser um 
aparelho que apenas permite testar 48 amostras de cada vez, não 
é ainda adequado para um laboratório de rotina. 
Apesar de ainda não ser utilizado no mercado, espera-se que 
em futuro próximo, após algumas alterações, contribua para a 
detecção de baixos níveis de troponina cardíaca facilitando o 
diagnóstico e evitando altas hospitalares inadequadas.  
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Cardiovascular disease is the largest single cause of death 
worldwide. The major single category of CVD is coronary artery 
disease resulting in acute myocardial infarction. 
Cardiovascular biomarkers have played an important role in 
the assessment of chest pain patients in the Emergency 
Department. Cardiac troponins have demonstrated a high 
sensitivity and almost absolute myocardial tissue specificity. They 
are considered the standard biomarkers for the detection of 
myocardial injury. 
Introduction of a higher sensitivity troponin assays allow 
measurement of concentrations below conventional levels of 
detection and have revealed a spectrum of circulating cardiac 
troponin in healthy subjects.  
In order to assess the analytical and clinical performance of a 
sensitive troponin assay that may aid in screening for, or for early 
detection of CVD, a number of tests on patients (percent normal 
study, precision study, linearity study, patient comparison study 
and a stability study) were performed.  
All the samples were tested between the Clinical Blood 
Sciences laboratory and the Research laboratory in St George’s 
Hospital NHS Foundation Trust in London according with ethical 
principles. 
The present study allowed to confirm the sensitivity of this 
new cardiac troponin I assay and proved that Singulex Clarity 
System is a potential analyzer in an analytical performance view. 
However, due to its long maintenance, quality control time 
evaluation and because it only allows testing 48 samples at a 
time, it does not have a usability required for a routine laboratory. 
Although not yet used in the market, after some changes, it is 
expected that in the near future it will contribute to the detection of 
low levels of cardiac troponin facilitating the diagnosis and 
avoiding inappropriate hospital discharges. 
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Background 
 
The sensitive troponin evaluation project (STEP) has been performed in the 
research and development laboratory at St George’s Hospital NHS Foundation Trust, 
London. The overall supervisor of this project is Dr. Paul Collinson 
(paul.collinson@stgeorges.ac.uk), consultant chemical pathologist and professor of 
cardiovascular biomarkers in St George’s Hospital NHS Foundation Trust and St George's 
University of London and Dr. David Gaze (D.Gaze@westminster.ac.uk), lecturer in 
Clinical Biochemistry at University of Westminster in London and honorary cardiac 
research scientist at St George’s Hospital. Prof. Paul Collison is an expert advisor to the 
National Institute for Health and Clinical Excellence (NICE) on cardiac biomarkers, and 
was responsible for developing and introducing troponin and B-type natriuretics to the 
United Kingdom. Dr. Gaze and colleagues have won a number of awards including two 
distinguished Abstract wards from the National Academy of Clinical Biochemistry as well 
as Diploma for Oral Presentation regarding D-dimer, natriuretic peptides and cardiac 
troponin in dialysis patients. 
The present thesis has been developed within the scope of the STEP project, to 
fulfill the Master of Molecular and Cellular Biology of Universidade de Aveiro. 
Singulex is a commercial start-up company pioneering Next Generation 
Immunodiagnostics (NGI). Singulex’s proprietary Single Molecule Counting (SMC™) 
technology is the backbone of NGI, and provides unprecedented ultra-sensitivity in the 
precision measurement of biomarkers. Singulex currently delivers SMC technology 
through its state-of-the-art clinical lab, which has performed in excess of 3 million NGI 
tests on more than 780000 patients. In 2016, Singulex launched the SMC-based Sgx 
Clarity™ instrument, a fully automated immune-analyzer, initially for NGI cardiovascular 
products, and to be followed by oncology, infectious disease, neurodegenerative and 
autoimmune diagnostic products. 
Singulex agreed with a number of partners including Prof Collinson as part of a 
multicenter assessment of the cardiac troponin I (cTnI) assay using the Sgx Clarity™ 
instrument to assess the analytical performance and clinical efficacy of the novel high 
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sensitivity assays. Data from the evaluation will allow refinement of analyser operation 
and provide information to extend and independently confirm the product claims of the 
company. The assay is currently the CE marked and is undergoing regulatory submission 
to the Food and Drug Administration (FDA) in the United States.  
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1.1. Cardiovascular disease 
 
The term cardiovascular disease (CVD) covers a range of conditions affecting the 
cardiovascular system. CVD is the largest single cause of death worldwide (Figure 1). The 
incidence of CVD is currently higher than cancer or other non-CVD comorbid condition. It 
is estimated that human longevity would be extended seven years if CVD were 
eliminated.
(1–10)
 
 
CVD includes ischemic heart disease (IHD), cerebrovascular disease, hypertensive 
heart disease, peripheral vascular disease, and structural abnormalities of the heart. The 
largest single category of CVD is coronary artery disease (CAD) resulting in acute 
myocardial infarction (AMI). 
(6,9,11)
 
CVD does not occur in single episodes but is a chronic progressive condition, 
beginning with plaque formation (a combination of inflammatory processes and lipid 
accumulation) leading to plaque destabilization, cardiac ischemia, cardiac myocyte 
necrosis and cardiac dysfunction
.(9)
   
CAD is characterized by atherosclerotic plaque buildup that begins early in life and 
slowly progresses over time. Atherosclerosis is an inflammatory disease, with a complex 
pathologic process, associated with lipid and other metabolic alterations. Atherosclerosis is 
a systemic disorder with high prevalence and commences very early in human life. 
Figure 1. Global distribution of CV in males. Adapted from Mendis Puska, 2011 
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Atherosclerosis can be affected by genetic, environmental, behavioral and dietary risk 
factors.
(12–15)
 
About 50% of cardiovascular deaths occur due to sudden cardiac death. These 
individuals may have only one of the risk factor but a significant proportion of these 
sudden deaths occur without any history of CVD. 
(1,5,9)
 
Acute coronary syndrome (ACS) is a major public health problem and occurs due 
to the rupture or erosion of the atheromatous plaque (Figure 2). The impact of plaque 
disruption and vessel occlusion will depend on the vascular anatomy. The key factors are 
the significance of the artery to overall blood supply and the degree of collateral circulation 
present. A mismatch between the supply of oxygen and the demand of the tissue will occur 
if the affected vessel is the main source of blood flow and there is no collateral circulation. 
A net reduction in supply compared to the demand results in tissue ischemia. The ensuring 
tissue hypoxia continues causing lack of tissue perfusion and may progress to 
cardiomyocyte necrosis. Clinically this is known as AMI. Post AMI survival results in 
remodeling processes in the myocardium and the development of cardiac failure. 
(5,9,12)
 
 
 
 
 
1.2. Cardiovascular risk factors and detection of CVD 
 
Elevated blood pressure (hypertension), usually considered as a systolic blood 
pressure exceeding 140 mmHg or a diastolic blood pressure exceeding 90 mmHg is one of 
the most prevalent risk factors for the development of CVD. 
(11,16)
 Hypertension is the most 
Figure 2. Development of an endothelial dysfunction, from foam cells to a ruptured atherosclerotic lesion.  
Adapted from Gaze, 2011. 
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significant single cause of cardiovascular accident (CVA, stroke) and a significant 
contributor to heart failure and CAD. Among the most prevalent causes of cardiovascular 
death are CAD, stroke, high blood pressure and heart failure.
(5,14,17)
 
One of the other Major contributors to CVD is a diet with high sugar, sodium and 
fat content, together with an environmental and lifestyle changes such as reduction in 
physical activity.
(11,12)
 Diet and exercise contribute to a clustering of cardiovascular risk 
factors including diabetes, hypertension, elevated triglycerides, increased low-density 
lipoprotein (LDL) cholesterol, and increased waist circumference, which are associated 
with progressive atherosclerotic disease.
(10,18)
 Smoking, although on the decline in 
westernised countries, is a major risk factor for CVD worldwide. 
(11)
 
Morbidity and mortality from CVD is largely preventable and is one of the public 
health goals worldwide. There are two main strategies: preventing CVD in the at-risk 
population before the onset of CVD by management of traditional cardiac risk factors, or 
focusing on a cohort with known CVD and modifying risk factors contributing to 
progression of CVD.
 (2,11)
  
The first step in the clinical management and early detection of CVD is 
identification of high-risk individuals. This step includes preventative strategies with 
assessment of multiple risk factors including age, hypertension, hyperlipidemia, diabetes 
mellitus, positive family history, tobacco use and obesity.
(2,8)
 Epidemiological evidence has 
shown that abdominal obesity is closely associated with the development of cardiovascular 
disease, and might be considered as an independent risk factor.
(11,19)
 Obesity predisposes to 
atherosclerosis with the consequence of a shorter life expectancy.
(19)
 It is know that ACS 
has a high heritability, the impact of which is far larger than the genetic effect on 
modifiable risk factors.
(14)
  
The next stage is active detection of underlying CVD. Risk stratification may have 
direct impact on choice of subsequent tests. For CVD detection some of the commonly 
tools are exercise tolerance test (ETT), pharmacologic stress testing, myocardial perfusion 
imaging, stress echocardiography and cardiac tomography. 
(2)
 The choice of test and 
diagnostic sensitivity and specificity will depend on the risk category, hence prior 
probability of disease. Although risk assessment tools and CVD detection modalities are 
widely used, they are not perfect and CVD patients can be misclassified into either a low 
or intermediate risk group. 
(2,8)
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The clinical symptoms of patients during the onset of ACS may include non-
specific chest pain, which is one of the leading causes for visits to the hospital emergency 
department (ED). These visits can be caused by more than a dozen medical conditions.
(3)
  
This complex nature of chest pain often makes it difficult for ED personnel to start 
necessary life-saving treatments for the patients suffering AMI. Current emergency 
medical evaluation of chest pain patients with suspected AMI includes obtaining the 
patient history, clinical examination, clinical observations (pulse, blood pressure) , the 
electrocardiogram (ECG), and blood testing for biomarkers of AMI, such as myoglobin, 
creatine kinase and cardiac troponins.
(3)
  
The accuracy for diagnosing AMI is still relatively low, however when using signs 
and symptoms, ECG and cardiac specific troponin together, the diagnostic accuracy is 
approximately 50%.
(3)
  
Prevention and control of CVD are possible and action is needed. In order to 
prevent CVD strategies are being implemented worldwide and including campaigns aimed 
at smoking cessation, reduction of salt consumption, increased physical activity, early 
detection and control of risk factors, decreasing consumption of unhealthy products, 
increasing physical activity and healthier diets, which is education in a proper lifestyle. 
 
(2,4,12) 
 
1.3. Cardiovascular biomarkers 
 
The first diagnostic test was the ECG, developed by William Einthoven. This test 
remains an essential tool for discriminating non-ST elevation  myocardial infarction (MI) 
from ST elevation MI.
(20)
  
Cardiac biomarkers, a broad subcategory of quantifiable and reproducible 
characteristics of biological signs, have played an important role in the diagnosis and 
management of patients with CVD. The largest challenge has been the identification of a 
biomarker with exclusive specificity for the heart, mainly because some cardiac 
biomarkers are not specific to a single pathway. A useful biomarker must have the 
following criteria: accuracy, that is the ability to identify individuals at risk; reliability, that 
is the stability of results when repeated at risk and therapeutic impact with early 
intervention.
(1,9,10)
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There are a number of cardiac biomarkers (Figure 3) to help in the identification of 
patients at risk of developing CVD, however many of this are not in use mainly because of 
cost, lack of an evidence base or the lack of a commercial assay. 
(9)
 
The development and introduction of new cardiac biomarkers has been increasing 
and evolving since the 1950s. The concept that tissue damage resulted in enzyme release 
that could subsequently be measured was the innovation that began the era of diagnostic 
enzymology. 
(9,20)
 
The first assay developed for testing for AMI was aspartate transaminase (AST). 
However this method was not suitable for routine clinical use and a spectrophotometric 
method was developed. In the meantime, it was reported that the measurement of C-
reactive protein (CRP) and fibrinogen could be used for the diagnosis of AMI. CRP is 
released from the liver during an acute phase response and has been demonstrated to be a 
strong predictor of future cardiovascular events. 
(9,20)
  
The second enzyme biomarker described was lactate dehydrogenase (LD).A rise in 
serum LD activity was associated with AMI. However the specificity of AST and LD was 
the main problem. AST was raised in liver damage and LD is found in a wide range of 
tissues and elevated in a variety of haematological, hepatic, malignant and musculoskeletal 
disease states. Serum lactate measurements were used however lactate has an extremely 
low cardiac specificity. 
(9,20)
  
The next to appear was creatine kinase (CK), where elevated levels were associated 
with muscle disease, in particular muscular dystrophy. CK was considered more useful 
than AST, especially when there was accompanying cardiac failure. This cardiac 
biomarker was followed by the development of improved assays for the MB isoenzyme 
(CK-MB). CK-MB is the predominant isoform found in myocardial tissue and is the 
largest fraction of total CK, observed post MI. CK-MB supersedes AST, LD and total CK 
measurement by demonstrating better sensitivity and specificity but still lacks absolute 
cardio specificity. 
(9,20)
  
Myoglobin, a respiratory pigment found in muscle cells, was the first non-
enzymatic marker used as a cardiac marker. Myoglobin also shows low cardio specificity 
due to elevated serum levels as a result of skeletal muscle injury or renal failure. 
(9)
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In 1979, World Health Organisation (WHO) publicized criteria for AMI, which 
included the measurement of biomarkers as part of the diagnostic strategies for patients 
presenting with chest pain and suspected AMI. 
(20)
 
Assays for cardiac troponins (cTn) were developed for cTnI and cardiac troponin T 
(cTnT) in 1987 and 1989, respectively. Early studies showed that elevated troponin levels 
in patients with unstable angina were associated with a significant risk of cardiac events, 
subsequently confirmed by a large number of investigators.
(20–22)
 In 1995 the first cTn 
assay, for cTnT was cleared by the FDA as an aid for the diagnosis of AMI. In 1992, the 
FDA cleared cTnI. 
(23)
 In 1999, the clinical chemistry community, followed by the 
cardiology community in 2000 recommended, cTn as the definitive biomarker for the 
diagnosis of AMI.
(23) 
 
When introduced cTn measurements were significantly more expensive compared 
to others assays. However the sensitivity and specificity for AMI diagnosis justified the 
cost of the new test, particularly in the ED, and the troponin measurement was “sold” as 
the “golden ticket”. Troponin measurement was embraced with enthusiasm, and some 
would say clinical judgment was abandoned.
(20,24)
 
Although the cTn assays has been established since 2000 as the preferred biomarker 
for the diagnostic of AMI, the original cTn assays have been progressively developed, 
redeveloped and reformulated to produce the current generation of sensitive and now high-
sensitivity assays.
 (24,25)
 
Figure 3. Cardiac biomarkers timeline, historical development of the cardiac markers.  AST, aspartate transaminase; LD, 
lactate dehydrogenase: CK, creatine kinase, CK-MB, creatine kinase-MB isoform; WHO, World Health Organisation, cTn, 
cardiac troponin; cTnI, cardiac troponin, cTnT, cardiac troponin T. Adapted from Gaze & Collinson, 2005. 
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According to a recent update of the universal definition of AMI, published in 2007 
by the Global Task Force, the diagnosis of AMI is based in the presence of unequivocal 
ECG changes and/or unequivocal biomarker changes; the history may be typical or 
atypical. Thus, the diagnosis required at least two of three criteria: positive clinical history 
of chest pain; unequivocal ECG changes or a rise and/or fall in cTn concentration (or CK-
MB, if cTn is not available), with at least one measurement within 24 hours of the cardiac 
episode above the 99
th
 percentile reference value.
(20,21,23,26–33)
 
Biomarkers have been shown to risk stratify symptomatic and stable ACS patients 
for both short-term (during admission) and long-term (over 8 months to 2 years) for major 
adverse cardiac events. The information provided by biomarkers from various CVD 
pathways has enormous potential for diagnostic and prognostic applications. 
(1)
 They 
should be used in along with clinical findings and the results of other diagnostic 
modalities. Any novel cardiac biomarker should prove clinically useful information 
combined with cost effectiveness in order to altering patient management and reduce 
mortality. 
(9,34)
  
Underlying, biomarker measurement is the ability to differentiate between healthy 
and disease states and the documentation of disease progression.
(35)
  
 
1.4. Cardiac troponin 
1.4.1. Troponin complex 
 
The troponin complex (Figure 4) (80 kDa) is located on the thin filament of the 
myofibril in all types of striated muscle (skeletal: slow twitch and fast twitch and cardiac 
muscle). It is formed from three subunits: subunit T (TnT: 37 kDa), subunit I (TnI: 22.5 
kDa) and subunit C (TnC: 18 kDa) which act as a molecular switch in the presence of 
intracellular calcium to drive muscle contraction. The T subunit is responsible for binding 
to the regulatory protein tropomyosin, which is located on thin actin fibers, providing 
structural anchorage. TnT also modules the response to intracellular Ca
2+
 by enhancing the 
interaction between myosin and actin. TnI affects the myosin-actin interaction, inhibiting 
the actin-myosin Mg
2+ 
dependent enzymatic hydrolysis of adenosine triphosphate that 
powers muscle contraction. TnC binds calcium ions released from the sarcoplasmic 
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reticulum. A number of proteins with high tissue concentrations are involved in muscle 
contraction however the cardiac troponins TnI and TnT are the only ones that have made 
the translation to a disease state biomarker due to their tissue specific isoform expression 
patterns.
 (9,10,36,37)
 Cardiac troponins are released from myocardial cells in case of overt 
myocardial injury.
(10,16)
 
Different forms of TnT and TnI are found in cardiac and skeletal  muscle, however 
TnC is not cardiac-specific and because of that it cannot be used in the laboratory 
diagnosis of cardiac injury.
(36,37)
  
 
 
 
 
 
 
 
 
 
 
 
 
1.4.2. Cardiac troponin T  
 
cTnT meadiates the binding of troponin to tropomyosin. cTnT is a 259 residue 
peptide which is highly charged. Charged residues are located along the entire length of the 
protein making it insoluble under low physiologic ion strength. The structure (Figure 5) of 
N-terminal variable domain varies with regard to a ~32 amino acids portion that is not 
present in the skeletal isoforms of TnT. The amino terminal is rich in acidic residues and 
the carboxyl terminal is rich in basic residues. The molecule is 17 nm in length and rod 
shaped, however it has polymorphic shapes when associated with TnC and TnI. Adult 
cardiac muscle normally expresses a single cTnT isoform, however there are 11 isoforms 
produced by alternative splicing in humans.
(9,36) 
 
Figure 4. Structure and localization of troponin complex. Adapted from 
Colinson, Boa, Gaze, 2002. 
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1.4.3. Cardiac troponin I 
 
TnI is an important modulator of myosin-actin interactions in cardiac muscle 
contraction and relaxation. cTnI is a 200 residue peptide and is globular in shape. It binds 
actin to hold the actin myosin complex in place. Conformational changes to TnI via Ca
2+ 
medicated TnC dislocates TnI removing the inhibition of tropomyosin binding to myosin 
thus causing muscle to contract. The most significant property of cTnI is its ability to 
induce different conformational changes in each of the proteins that it influences. cTnI also 
binds tropomyosin, TnT and TnC. 
(9,36)
  
The human cTnI chain (Figure 6) consists of five domains: the N-terminal domain, 
the IT arm, the inhibitory domain, the regulatory domain and the C-terminal mobile 
domain. Residues 1-31 represent a cardiac-troponin-specific region, which plays a crucial 
role in the interaction of cTnI with cTnC and in the regulation of muscle contraction. 
(36)
 
 
Figure 5. Cardiac troponin T – basic structure and interaction with other compounds of thin filament. Domain 
structure of human cardiac troponin T. Proteins of the thin filament that interact with the relevant regions of 
the TnT molecule are indicated in ovals. T1 and T2, regions of interaction with tropomyosin. Adapted from 
Katrukha , 2013. 
Figure 6. Cardiac Troponin I – basic structure and interaction with other compounds of thin filament. Domian 
structure of human cardiac troponin I. Proteins of the thin filament that interact with the relevant regions of the 
TnI molecule are indicated in ovals. N-TnC and CTnC, N-and C-terminal domains of TnC, respectively; Tm, 
tropomyosin. Adapted from Katruha, 2013 
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1.4.4. Troponin genetics 
 
Skeletal and cardiac muscles develop from different embryonic cell precursors, but 
share a common developmental pathway. Many genes from both cell types are cross-
expressed during embryonic development. There are different forms of TnI and TnT in 
slow twitch skeletal, fast and cardiac muscle.
(9,37)
 
 During the development of fetal muscle, all troponin isoforms are expressed 
simultaneously. A diversity of all three TnT could potentially exist as a result of alternative 
splicing of mRNA from a single gene transcript, but very few spliced variants are 
expressed at the protein concentration. 
(9,37)
  
Foetal cTnT isoforms are transiently expressed however these are down regulated 
in adult cardiac tissue. In human fetal skeletal muscle, a fetal isoform of cTnT is 
proportionally low in concentration. A fetal exon with sequence homology to adult fast 
sekeletal TnT (sTnT) and cTnT has been described. Fast or slow sTnT are not detectable in 
fetal cardiac tissue. Expression of embryonic isoforms in the adult heart has been 
associated with the deterioration of cardiac function and heart failure. 
(9,36,37)
  
At mid fetal development, the cTnT gene is up regulated in cardiac myocytes but 
suppressed in skeletal myocytes. cTnI is not expressed during embryonic or fetal 
development and is only detectable in adult cardiac tissue. During first nine months of life, 
sTnI is switched to cTnI expression, this means that cTnI may be not of useful value in 
neonatal cardiology. 
(9,37)
  
 
1.5. Cardiac troponin for the diagnostic of acute coronary syndrome 
 
Cardiovascular biomarkers have played an important role in the assessment of chest 
pain patients in the ED. The clinical role of cTn measurement can be divided into three 
clinical categories (Figure 7) based on the presenting ECG and clinical assessment of the 
patient. These are: patients presenting with ST segment elevation myocardial infarction 
(STEMI); patients with questionable ACS at high risk of non-ST elevation myocardial 
infarction (NSTEMI) and patients with questionable ACS at low risk of NSTEMI. Patients 
with STEMI are highly specific for AMI and they are considered patients who will benefit 
from immediate revascularisation. In these patients, the role of cTn measurement is to 
confirm the final diagnosis. The ECG is therefore the selection test to identify patients who 
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will benefit from immediate treatment to salvage myocardial tissue and not as a diagnostic 
test for AMI. 
(9,24,38)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Non ACS 
troponin 
elevation 
Initial cTn>99 
th percentile 
no significant 
change at 1h 
ETT or 
non-
invasive 
imaging 
or no 
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ETT or 
non-
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or no 
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Injury 
Initial cTn 
>LOD 
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Figure 7. Algorithm for triage of the patients presenting to the ED with chest pain suggestive of AMI using high-sensitivity troponin 
measurements. Adapted from Paul Collinson, 2016. 
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1.6. Cardiac troponin immunoassay 
 
In the last few years, several generations of assays have been available for cTnT 
and cTnI. The first generation of immunoassays used in the detection of cTnT was 
developed by Katus in 1991. Three years later kits for cTnI measurement appeared. There 
are many commercial cTnI assays that target different epitopes and multiple calibrators 
available on the market. The following high-sensitivity or ultrasensitivity cTnI are 
available: Abbot ARCHITECT, Beckman Acess, Singulex Erenna, Siemens Vista and 
Siemens ADVIA CentaurTnI-Ultra. However, the only hs cTnT assay, which is generally 
available, is patented under license by Roche Diagnostics GmbH (previously Boehringer-
Mannheim Immunodiagnostics GmbH). 
(9,36)
 
The European Society of Cardiology and the American College of Cardiology 
(ESC/ACC) recommend a cutoff value at the upper 99
th 
of values for a reference 
population of healthy individuals and imprecision defined as <10% for high-sensitivity 
cardiac troponin (hs-cTn) assay. Assays that meet this diagnostic standard are defined as 
contemporary sensitive. Assays that also enable cTn detection in over 50% of the general 
population are considered high sensitivity. This sensitivity assays allow to reduce the time 
interval required for diagnosing AMI but also to improve diagnostic accuracy. The 
majority of contemporary assays in the market currently do not meet the guidelines; 
however studies have provided evidence that shows that assays with an imprecision up to 
20% coefficient of variation (CV) do not significantly affect diagnostic accuracy or risk 
stratification. The assays, which are capable of quantitating cTn at level well below the 
lowest cTn concentrations seen in healthy subjects should be designates as ultras-sensitive. 
Assays with imprecision > 20% should be used with caution.
(21–24,29,32,36,39–47)
 
Over the past several years, manufacturers of cTn assays have improved the quality 
specifications of assays to allow for more precise quantitation of low cTn concentrations 
by introducing the highly sensitive cTn assays. The difference between these new hs assays 
from their predecessor is the ability to measure very low cTnT and cTnI concentrations (1-
20 ng/L, well below the limit of detection of the contemporary assays) with an excellent 
imprecision (CV≤10%) at and below the assay’s 99th percentile value. This added 
sensitivity allows hs cTn assays to reliably measure concentration in almost 100% of 
healthy individuals. Measurement of small cTn concentration changes or delta within the 
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normal range may provide new opportunities to screen asymptomatic 
populations.
(23,26,28,32,34,36)
 
Measurement of cTnT and cTnI is by immuoassay, a biochemical test that 
determines the presence or the concentration of a substance in solution that frequently 
contains a mixture of substances. The test is based on the ability of an antibody to bind 
with high specificity to a specific region of the molecule being testes, the antigen. As final 
product of this reaction the immunoassay produce a signal in response to the antigen-
antibody binding. Some immunoassays depend on the use of an analytical reagent that is 
associated with a detectable label. The majority of immunoassays methods for detecting 
cardiac biomarkers are sandwich assay (Figure 8), where the antigen (for example 
troponin) in the unknown is bound to specific anti-troponin capture, antibody. A secondary 
labelled antibody binds to form and complex antigen-antibody-antibody. The amount of 
labelled antibody present is measured which is directly proportional to the amount or 
concentration of antigen present in the sample.
(9,21,36) 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
The different antibody used in the commercial assays may have different 
sensitivities to the antigen contributing to the variations in concentrations obtained using 
different immunoassay systems. The electrochemiluminescence immunoassay (ECLIA) 
with ruthenium, the antibody of reaction, is used in the hs cTnT assay (Roche Diagnostics, 
Figure 8. Sandwich immunoassay principal.  Adapted from David, 2011. 
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USA). Most of these assays are fully automated and are intended for use with special 
immunoassay analyzers.
(36,37)
 
The recent Ultra-sensitive Erenna® Cardiac Troponin-I Immunoassay, under 
license by Singulex Inc. San Francisco, USA, is considered the most sensitive cTnI assay 
for research purposes. This hs-cTnI assay utilizes a unique immunoassay instrument with 
patented, digital, single-molecule detection of highly precise quantification of low-
abundance biomarkers. The new assay uses single-molecule counting technology, which 
uses single-photon fluorescence detection. Preliminary studies demonstrated a detection 
limit of 0.2 ng/L and 10% CV at 1.8 ng/L, surpassed many other commercial assays. 
However, with such sensitive limits of detects, the possibility that low-level of nonspecific 
binding events contribute to cTnI measurements cannot be discarded. 
(36,41,43,48)
 
SMC™ was introduced in 2007 and since that introduction, immunoassays using 
the Erenna have allowed for the detection of low concentration biomarkers at levels that 
were previously undetectable. Several improvements have resulted in the development of 
an SMC™ scanning reader which forms the basis of the Singulex Clarity™ System, 
designed to be the most sensitive, fully-automated, next generation immunoassay platform 
available.
(49–51)
  
Singulex Clarity™ System (Figure 9), a fluorescent immunoassay has been 
developed to measure cTnI, which utilizes SMC™. This assay utilizes two monoclonal 
capture antibodies and two monoclonal detection antibodies, with one of each specific for 
the stable central portion of cTnI, and the other specific to the N- or C- terminus to 
maximize its ability to detect post-translationally modified cTnI in circulation. Biotinylated 
capture antibody are conjugated to paramagnetic microparticles to enable capture of cTnI 
antigens, and fluorescently labeled detection antibodies enable quantitation by the 
proprietary SMC™. The capture and detection antibodies are incubated with the samples in 
a one-step reaction, followed by a washing step. The immunoassay sandwich is 
subsequently eluted from the paramagnetic microparticles with a low pH elution buffer and 
the fluorescent signal is measured by the Singulex Clarity System. 
(49,50,52)
 
The Erenna®, from the same company, has been shown to identify low-abundance 
of biomarkers with unparalleled sensitivity, precision, and accuracy. The Singulex 
Clarity™ System utilizes a second generation scanning-based detection system which 
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maintains the exquisite sensitivity of the Erenna® while improving upon the throughput, 
dynamic range, and usability of that system.
(49,50)
  
There are challenges and opportunities in the high sensitivity assay era, in terms of 
the analytical performance and validation/interpretation procedures for the laboratory and 
the relevance in the clinical setting. Significant improvements have been made in 
performance, including standardization, precision and sensitivity. However all the troponin 
assays require substantial additional analytical and clinical validation before to clinical 
use.
(20,21,27,35)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.7. Analytical measurement of cardiac troponin 
 
 The cardiac troponins are released from the myocardium into the circulation in the 
first few hours following a period of ischaemia or infarction. Typically, following ACS the 
peak in serum concentration is seen at 12-24h.
(37,40,42,53) 
Cardiac troponin measurement are 
used for the detection of myocardial damage and play a central role in aiding the diagnosis 
of ACS.
(21,27,36,37,42,54)
 cTnT and cTnI have demonstrated a high sensitivity and almost 
absolute myocardial tissue specificity. They are the standard biomarkers for the detection 
of myocardial injury and prognostic evaluation of patients with ACS and without.
(21,27,28,37)
  
At this time, a new generation of cTn assays, hs-cTn, is commercially available. 
These assays allow measurement of concentrations below conventional levels of detection 
and have revealed a spectrum of circulating cTn concentrations spanning low and high 
Figure 9. Singulex Clarity™ System.  Adapted from A. 
Bartolome, 2015. 
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levels in both healthy subjects and in patients with overt cardiovascular disease. Due to this 
clinical value, hs-cTn is been adopted as the ‘gold standard’ cardiac biomarker following 
the universal definition of AMI. cTn testing has become the standard for AMI detection as 
well as a challenge to clinicians to be able to discern an increased cTn between the 
diagnosis of AMI and a pathological mechanism in the absence of overt ischemic heart 
disease. 
(10,21–27,32,37,40–42)
 
Introduction of a higher sensitivity troponin assays allows diagnosis sooner than 
older generation assays and made possible the detection of small increases of cTn 
concentration. The hs-cTn assay allow and rule-in and rule-out of AMI potentially within 
2-3h of admission. With these assays it may be possible to diagnose AMI earlier. Also, the 
use of cTnT and cTnI results in approximately 33% of patients previously classified as 
unstable angina being reclassified as AMI. 
(20–22,26,38)
  
Cardiac troponin measurement has been the mainstay for diagnosing ACS and 
offers considerable benefit for stratification of the risk for future adverse cardiac 
events.
(21,22,48)
 Moreover, in individuals considered “normal” without know cardiovascular 
disease, increased cTn concentrations are indicative of a significantly higher risk of 
death.
(28)
  
Cardiac troponins, recognized as biomarkers for AMI, are the standard biomarkers 
for diagnosis of myocardial damage. However, some studies in ultra-high sensitivity assays 
show that low levels of elevated troponin yield prognostic information for individuals 
without know CVD, mainly because of progressive improvement in assay sensitivity that 
has resulted in an increasing range of clinical conditions, where troponin elevation is 
detected in patients who do not have AMI. 
(1,24)
 Therefore, it has been postulated that 
sensitive cTn, given the detection in asymptomatic healthy people without a history of 
CVD; may be of value in identifying subjects at long term risk of ACS, in the other words, 
cTn may have a role in primary prevention.
(21,33,55)
 
The clinical importance for a very hs-cTn assay can be notification in 3 major 
areas, where this assay have the potential to improve current practice: monitoring of 
therapeutic drugs that have the potential to cause cardiotoxicity, earlier diagnosis than is 
currently possible and improved stratification of the risk for future adverse cardiac events 
among patients being evaluated for AMI.
(48)
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It is important to remind that cTn elevation is not a marker of ACS itself, but a 
marker of cardiac cell damage acute or chronic and whatever the cause, troponin elevation 
is always prognostic. AMI remains a clinical diagnosis of which cTn aids in the final 
decision. 
(9,24)
 
 
1.8. Cardiac troponin elevated in non-ACS conditions 
  
cTns are elevated in other conditions without a primary cardiac pathology, these 
include cardiac trauma, renal failure, autoimmune conditions, drugs and toxin induced 
cardiotoxicity and exercise induced release. All of those factors can contribute to confusion 
in the emergency clinical setting. 
(9)
  
There is a growing evidence base for the detection of cTnT and cTnI in chronic 
disease states, for example in patients with renal failure the troponin is commonly elevated. 
Studies have demonstrated that both cTnT and cTnI are elevated in renal failure and that 
such elevation carries prognostic significance. In patients with end stage renal disease 
(ESRD) cardiovascular events are the largest single cause of death. 
(9,37,38,56)
  
Another condition that contributes to an increase of troponin is a physical exercise. 
Practice of exercise plays an important role in the prevention of CVD. However, there is an 
increasing release of cTn following exercise. The mechanism by which cTn is released 
following prolonged or strenuous exercise remains uncertain.  However, this knowledge 
enables physicians to make informed clinical decisions and use cTn testing appropriately in 
patients who present following exercise. 
(9,32,57)
 
Moreover, the release of cTn following drug therapy is also considerable interest 
for diagnosis, monitoring and drug safety studies. It has been documented that cocaine 
ingestion can induce the release of cTn and could potentially be a cause of diagnostic 
confusion in patients presenting with chest pain. 
(38)
 
cTn is not an exclusive biomarker for the diagnosis of AMI. It is becoming clear 
that multiple mechanisms contribute to troponin elevation. A number of secondary 
ischemic and non-ischemic cardiac injuries are known to be associated with elevated cTn, 
which can include necrosis, apoptosis, normal myocyte cell turnover, cellular toxicity, 
neurohormonal activation, release of proteolytic troponin degradation products, increased 
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cell-membrane permeability due to integrin-mediated “stretch” mechanisms and formation 
and release of membrane blebs.
 (21,22,36)
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1.9. Justification of the study 
  
CVD are not only debilitating for patients and their families, they also threaten the 
sustainability of our healthcare systems. CVD is a major contributor to rising healthcare 
expenditure, contributing for a large proportion of emergency care budgets. 
(5,21)
 
The condition of heart failure may be difficult to diagnose due to the presentation of 
non-specific symptoms. There is a risk group of patients who, if not correct diagnose, 
stands to be miscategorized and exposed to the potential catastrophic events of undetected 
CVD.  Furthermore, the differential diagnosis of heart failure often requires numerous 
expensive procedures to obtain surrogate measures of cardiac function. 
(1,2,47,58)
 
With all the consequences of undiagnosed CVD, early detection and frequent 
monitoring of both traditional risk factors and novel biomarkers has the potential to save 
lives and reduce unnecessary costs due to CVD morbidity and mortality. 
(1)
 Clinical 
decision support tools are powerful process with the potential to provide faster diagnoses, 
modifying potential risk factors, improved prediction performance, and reduced medical 
costs by eliminating unnecessary testing.
(1,2)
 However, the importance of addressing 
improved diagnostic capabilities during the early onset of ACS for life saving and 
improvement of clinical outcomes remains as an unmet global need.
(3)
  
There is still an urgent need for identifying additional biomarkers for a more rapid 
detection of acute cardiac ischemia, in order to substantially improve the diagnostic 
accuracy, to achieve timely treatment, to improve clinical outcomes of patient survival and 
timeliness for initiating medical treatments. Anything which could be used to refine the 
initial assessment of the patient prior to referral to raise the probability of a correct 
diagnosis is therefore of interest.
(3,22)
  
Furthermore, even the clinical utility to detect low levels of cTn in healthy 
population samples is currently unknown, cTn measurements may be very useful to 
improve our mechanistic understanding of cTn turnover and its associations with 
cardiovascular risk factors. 
(16) 
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1.10. Aim of the Study  
 
Recently, there has been the development of hs-cTn assays for routine clinical use. 
Although these assays are an order of magnitude more sensitive than the original 
"contemporary sensitive" troponin assays, they typically have a detection limit of around 1 
ng/L and do not completely measure troponin across the reference interval. The 
measurement of very low troponin values with low analytical imprecision may facilitate 
very rapid diagnosis of myocardial infarction using the recently proposed one hour rule out 
algorithms of the European Society of Cardiology.  
The purpose of this study is to assess the analytical and clinical performance of a 
sensitive troponin assay that may aid in screening for, or for early detection of CVD.  
The objective of the current study is the analytical validation and clinical suitability of 
the Singulex high sensitivity cardiac troponin I assay for routine clinical use. Then, the 
following tasks were planned: 
 Evaluation the imprecision profile of the Singulex assay; 
 Evaluation the ability of the cTnI assay on the Sgx Clarity System to detect cardiac 
troponin-I in self-declared healthy individuals; 
 Compare the results of cardiac troponin-I from routine high-sensitivity troponin 
such as the Abbot STAT High Sensitive Troponin-I assay on the Abbot Architect 
system; 
 Compare the results of cardiac troponin-I from routine high-sensitivity troponin 
such as the Roche Sensitive Troponin-t assay on the Cobas 8000 system; 
 To assess the usability of the system for routine clinical measurement of cardiac 
troponin from the operator perspective and laboratory process flow impact.
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Chapter II –  
Material and Methods 
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2.1. Organization of study 
This project was divided in five parts: percent normal study, precision study, 
linearity study, patient comparison study and stability study. All these parts of the project 
belong to the verification method.  
Study operators were trained to the proper operation of the Sgx Clarity System and to 
the Instructions for Use of the Sgx Clarity cTnI assay by qualified Singulex staff before the 
start of study testing. 
All the samples were tested in the Singulex Clarity System, in the Cobas 8000, 
Roche Diagnostics, and/or in the Abbot Architect. 
 
 
2.2. Local of study  
This project was undertaken in St George’s Hospital NHS Foundation Trust in 
Tooting in the London Borough of Wandsworth. The samples were tested between the 
Clinical Blood Sciences laboratory and the Research laboratory. 
 
2.3. Percent normal study   
2.3.1.  Duration and period of study  
 
This study stared in 14 of March of 2017 and lasted until 06 of April of 2017, with 
duration of 4 weeks. 
2.3.2. Population of study and sample size 
 
Three hundred sixty (360) de-identified specimens from self-declared healthy 
donors who were not suspected to have cardiovascular disease were tested in duplicate 
(720 tests) using Singulex Clarity cTnI Assay. These samples were provided by the 
Singulex team. Informed consent was obtained from all the donors.  
The selection of the individuals for the percent normal study was based on a health 
criterion: 
 General good health; 
 At least 16 years old (depending on state); 
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 Weigh at least 110 pounds (~49,89 Kg). 
 
Conditions that would exclude donors: 
 Hemoglobin or Hematocrit levels is below what’s safe or blood donation; 
 Blood pressure or pulse is too high or low; 
 If the donors is under treatment for a variety of illnesses like cancer, heart 
disease or certain blood diseases; 
 Tattoos from a non-licensed/ regulated facility; 
 Body piercings; 
 Cold or flu; 
 Had a recent blood transfusion; 
 Hepatitis; 
 HIV/AIDS; 
 Certain international travel (abroad diseases); 
 Organ/ tissue transplants; 
 Pregnancy; 
  Sexually transmitted diseases. 
·        
2.3.3. Specimen storage 
 
Singulex provided a complete set of specimens that were shipped on dry ice, 
arrived frozen and were stored at -20ºC until ready to use. 
Singulex also provided reagent cartridge kit (Table I), Sgx Clarity cTnI calibrator 
kit (Table II), Sgx Clarity cTnI control kit (Table III), Sgx clarity buffer kit(s) (Table IV) 
and primary Sgx Clarity consumable kit(s) (Table V). Sgx Clarity cTnI assay reagents, 
controls, calibrators, buffer and consumable kits were stored in accordance with the 
conditions described in the respective package inserts and instructions for use. 
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Table I. Reagent cartridge kit. 
Assay 
Component 
Description Contents No. of 
bottles 
Fill 
volume 
 
 
 
 
Reagent 
cartridge 
contents 
Capture reagent: 
pre-diluted 
capture reagent 
(96 test capacity) 
Streptavidin-labeled 
paramagnetic microparticles 
coated with Capture 
Antibodies, HEPES buffer, 
sodium azide as preservative 
 
 
1 
 
 
4.5 mL 
Detection 
reagent: pre-
diluted detection 
reagent (96 test 
capacity) 
Fluorescently-labeled  
Detection Antibodies 
MAbMF4 and Mab16A12, 
HEPES buffer, sodium azide 
as preservative 
 
 
2 
 
 
4.4 mL 
 
 
Table II. Sgx Clarity cTnI Calibrator Kit. 
Assay 
Component 
Descrition Contents No. of 
Bottles 
Fill 
Volume 
 
 
cTnI 
calibrators 
 
Human 
cardiac 
Troponin I 
calibrators 
- Troponin I in human 
protein matrix 
- Target concentrations: 
0 pg/mL; 17 pg/mL 
(range 12-35 pg/mL); 
21,250 pg/mL (range 
19,125-23,375 pg/mL) 
 
 
 
3 
 
 
 
0.75 mL 
 
Table III. Sgx Clarity cTnI Control Kit. 
Control Target Approximate Concentration (pg/mL) 
Control L-1 7.00 
Control L-2 20.0 
Control L-3 40.0 
Control L-4 10000 
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Table IV. Sgx Clarity Buffer Kit(s) 
Assay 
Component 
Description Contents No. of 
Bottles 
Fill Volume 
Elution Buffer General, on-
board 
Glycine, Triton X-100 1 30 mL 
 
Wash Buffer 
General, 10x 
concentrate, 
stored off board 
Borate buffer, Triton 
X-100, ProClin 950 as 
preservative 
 
1 
 
1.0 L 
 
 
 
Table V. Primary Sgx Clarity Consumable kit(s) 
Consumable 
Component 
Description Contents No. of Components 
 
Detection Vessel 
Clarity instrument-
specific 96-well 
microtiter 
100 detection vessels 
per case plus 
instructions for use 
3 detection vessel 
capacity per 
instrument 
 
Reaction Vessel 
Clarity instrument-
specific stripwells with 
8 reaction wells per 
strip 
1,600 strip wells per 
case plus instructions 
for use 
8 reaction vessels per 
stack; 10 
stacks/instrument 
load 
 
 
2.3.4. Type and sampling technique  
 
In this part of the study all the samples were tested in the Singulex Clarity™ cTnI 
assay, using single-photon fluorescence detection for the quantitation of cTnI, in 
ethylenedaiminetetraacetic acid (EDTA) plasma on the Sgx Clarity™ System. 
The Sgx Clarity System requires a daily and weekly maintenance. Daily 
maintenance encompasses ‘start of the day’, where the consumables are changed and some 
maintenance is performed, and ‘end of the day’, where the wastes are discarded and some 
maintenance is performed. Weekly maintenance is performed once per week, where some 
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solutions are changed and some cleaning maintenance is performed. After the ‘start of the 
day’ the Sgx Clarity System is ready to start processing. 
A three-point calibration of the Sgx Clarity System were performed on the first day 
of testing, before the first sample run on the system, and then as prompted by the Sgx 
Clarity System software, or when assay controls are out of specification. Three replicates 
of each of the 3 provided calibrators are tested in each calibration run for a total of 9 
calibrator tests. A volume of 500 µL was used per each calibrator level. 
After the calibration finished without any error the Sgx Clarity cTnI Controls were 
tested. All four levels of these controls were tested once per day, before the first run of the 
day. A volume of 400 µL was used per each control level. Singulex provided matching, 
labelled secondary tubes for loading specimen aliquots onto the Sgx Clarity System. 
Specimens were processed according to the instructions provided in the Sgx Clarity cTnI 
assay Instructions for Use. Up to 48 specimens may be included in a single run. 
For each run, the aliquot tubes were removed from the freezer and they were left to 
thaw at room temperature for a minimum of 20 minutes. Each aliquot had 500 µL of donor 
plasma.  The aliquots were then vortex and centrifuged at 11300 xg for 10 minutes at room 
temperature. 
At that moment just 300 µL of each aliquot were transferred to a fresh tube, without 
the supernatant, before being analysed in the Sgx Clarity System. 
The instrument recognized the barcodes when they were loaded and it 
automatically created an order. 
 
 
 
2.4. Precision study  
Samples utilised during this phase of the study were residual samples left over from 
routine analysis that would otherwise have been discarded and on whom testing was 
complete. Prior ethical approval for use of such material had been obtained.  
2.4.1. Duration and period of study  
 
This study stared in 30 of March of 2017 and lasted until 18 of April of 2017, with 
duration of 3 weeks. 
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2.4.2. Population of study and sample size 
 
 
Pooled human serum samples were created using spare excess serum, no more than 
48 hours old, collected from multiple anonymised patient samples, in the Clinical Blood 
Sciences laboratory of St George’s Hospital, and pooled to form a base pool with a volume 
of approximately 260 mL. All patients were aged between the age of 18 and 35. All of 
these samples were tested on Roche equipment and all of them had a result of <3 ng/L for 
cTnT. 
To create a pool to dilute, spare excess serum was also collected from multiple 
anonymized patient samples (around 20 patients) with a cardiac troponin T value > 5000 
ng/L and pooled to form a concentrated pool with a volume of approximately 20 mL. All 
samples were collected in Chemical Pathology laboratory of St George’s Hospital, and 
they were no more than 48 hours old. 
Both pools, the base and the concentrated pool, were run on the Sgx Clarity System 
and the cTnI concentration of the pools was recorded.  
Based on the cTnI values given by the Singulex assay, some successive dilutions 
were made spiked the base pool with the concentrated pool to give approximate 
concentrations of 0.5, 1.25, 3.0, 5.0, 10.0, 50.0, 100.0 and 300.0ng/L. These concentrations 
allowed to cover the range between a low limit of detection (0.5 ng/L) and a high value 
representative of unequivocal AMI diagnosis.  
Aliquots of the different diluted pools with 400 µL each were prepared and stored 
at -20ºC in the freezer. 
 
2.4.3. Type and sampling technique 
 
 In this part of the study all the samples were tested in the Singulex Clarity™ cTnI 
assay and on the Cobas 8000, for cTnI and cTnT, respectively. The aliquots were removed 
from the freezer and they were left to thaw at room temperature for a minimum of 20 
minutes. The aliquots were then vortexed, centrifuged at 11300 xg for 10 minutes at room 
temperature, and finally the supernatant was transferred to a fresh tube before being 
analysed. 
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As part of this study an intermediate precision data and a repeatability precision 
data were done. For intermediate precision data studies, five aliquots of all of the different 
pools were measured at the same time in a single run. This procedure was performed five 
times either on different days or in the morning and afternoon of the same day. Theses 
aliquots were tested on both the Roche cTnT assay and the Singulex cTnI assay. For 
repeatability precision data studies, twenty aliquots of the same pool were measured at the 
same time on a single run. This was repeated for each of the different pools and for the 
different levels of the provided Singulex quality control (QC) material. This repeatability 
study was only performed on the Singulex cTnI assay.  
In addition, to the precision data studies for the pooled samples the four different 
levels of the Controls provided by Singulex were also run every day the assay was used on 
the Singulex cTnI assay. The first twenty five results, across different days, for the QC 
materials were used to calculate the mean, +/- 2 standard deviation (SD) and the % of CV.  
 
2.5. Linearity study  
2.5.1. Duration and period of study  
 
This study was performance in 18 of April of 2017. 
 
2.5.2. Population of study  
 
Pooled human serum samples were created using spare excess serum, no more than 48 
hours old, collected from multiple anonymised patient samples, in the Chemical Pathology 
laboratory of St George’s Hospital, and pooled to form a base pool with a volume of 
approximately 20 mL. All patients were aged between the age of 18 and 35.  
The samples were pooled to form two pools, around 10 patients samples per each pool 
with volumes of approximately 10 mL per pool. The pools were tested in the Sgx Clarity 
System and the values for cTnI were of either approximately 350 ng/L or approximately 
25ng/L 
To dilute the pools (350 ng/L and 25 ng/L), pooled human serum samples were 
created using spare excess serum, no more than 48 hours old, collected from multiple 
anonymised patient samples, in the Chemical Pathology laboratory of St George’s 
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Hospital, and pooled to form a base pool with a volume of approximately 20 mL. All of 
these samples were tested on Roche equipment and all of them got a result of <3 ng/L for 
cTnT. 
 
2.5.3. Type and sampling technique  
 
In this part of the study all the pools were tested in the Singulex Clarity™ cTnI 
assay.  
The 350 ng/L and the 25 ng/L pools were diluted, in a triplicate, with the diluent 
pool separately in triplicate to give the following dilutions: neat, 80%, 60%, 40%, 20%, 
15%, 10% and 5% in a final volume of 400µL.   
The triplicate dilutions were all vortexed, centrifuged at 11300 xg for 10 minutes at 
room temperature, then transferred to a fresh tube before being analysed on the Singulex. 
Mean values of each dilution were then calculated.  
 
 
 
2.6. Patient comparison study  
2.6.1. Duration and period of study   
 
This study was performance in 20 of April of 2017. 
 
2.6.2. Population of study  
 
Spare excess serum from 60 anonymised patient samples was collected from 
Chemical Pathology laboratory of St Helier Hospital, in London. These samples had been 
run on the Abbot Architect STAT HS Troponin I assay. Samples were no more than 48 
hours old and had been stored at 4ºC. 
 
2.6.3. Type and sampling technique  
 
In this part of the study all the 60 samples were tested on the Singulex Clarity™ 
cTnI assay and on the Roche cTnT assay on the same day. The serum samples with a 
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400µL of volume were vortexed, centrifuged at 11300 xg for 10 minutes at room 
temperature and then transferred to a fresh tube to be analysed.   
  
 
 
2.7. Stability study  
2.7.1. Duration and period of study  
 
This study stared in 08 of May of 2017 and lasted until 12 of May of 2017, with 
duration of 1 week. 
 
2.7.2. Population of study   
 
In order to verify the stability of Singulex cTnI assay, an experiment was performed 
to investigate the effects of time and temperature. 
Pooled human serum samples were created using spare fresh (all samples were less 
than 6 hours old) excess serum collected from multiple anonymised patient samples, in the 
Chemical Pathology laboratory of St George’s Hospital, and pooled to form a base pool 
with a volume of approximately 60 mL. All patients were aged between the age of 18 and 
35. All of these samples were tested on Roche equipment and all of them had a result of <3 
ng/L for cTnT. 
To create a pool to spike the low troponin pool, spare excess serum was also 
collected from multiple anonymized patient samples with a high cardiac troponin T value 
and pooled to form a concentrated pool with a volume of approximately 20 mL. All 
samples were collected in Chemical Pathology laboratory of St George’s Hospital. 
The low troponin pool was spiked with the high troponin pool to produce different 
cTnI concentrations. The baseline concentration (day 0) of each of the pools was 
determined by running aliquots in duplicate on the Sgx cTnI Clarity System.  
Aliquots of 400 µL of the different diluted pools were stored at room temperature 
(+/- 21ºC), -4ºC or -20ºC in the freezer. 
For the 4 subsequent days (every 24 hours), two aliquots of each pool were tested 
on the Sgx Clarity System.  
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2.7.3. Type and sampling technique 
 
In this part of the study all aliquots were tested on the Sgx Clarity System for cTnI. 
In each day, two frozen aliquots were removed from the freezer and they were left to thaw 
at room temperature for a minimum of 20 minutes.  Together with two aliquots stored at 
room temperature and two aliquots stored at -4ºC, the aliquots were vortexed, centrifuged 
at 11300 xg for 10 minutes at room temperature, and transferred to a fresh tube to be 
analysed. 
 
2.8. Statistical treatment 
All the data was analysed using the program Analyse-IT, which was added on the 
Excel.  
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3.1. Percent normal study   
In order to evaluate the ability of the Sgx cTnI assay on the Sgx Clarity System to 
detect cTnI, three hundred sixty de-identified specimens from self-declared healthy donor 
who were not suspected to have cardiovascular disease were tested in duplicate (720 tests). 
From a total of 360 samples, 2 of them could not be included, one sample was missing and 
one was removed as outlier. All the duplicate results were averaged, resulting in a 
concentration range of 0.13 – 11.27 pg/mL of cTnI and a confidence interval (CI) of 90%, 
as shown on Figure 10.  
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Comparison between the cTnI concentration and the frequency of all the samples 
tested. 
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Figure 11 compares the age and sex of each individual with the concentration of cTnI.  
 
 
Figure 11. Comparison between the age and cTnI concentration (left) and between the sex and cTnI 
concentration (right). The boxes represent interquartile range (IQR), mid line (triangle) represent median and 
whiskers represent 5th and 95th percentiles. 
3.2. Precision study  
3.2.1. Singulex intermediate precision data 
 
All the pools were measured in the Sgx Clarity System. However some of them 
gave unexpected results (Table VI), which are being investigated by Singulex. When the 
result came with a “flyer” or failed sample occurred in a run, the remain samples from that 
pool within the run were not used to calculate precision data.  
As mentioned before four different levels of QC provided by Singulex were also 
run every day and the first twenty five results, across different days, were used to calculate 
the mean, +/- 2 SDs and the % CV. All the results are shown in Table VII.  
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Table VI. Concentrations of all pools tested in the Sgx Clarity System. 
 Pools (ng/L) 
0.5 1.25 3 5 10 50 100 300 
 
30/03/2017 
(aborted rum) 
0.51 1.19 2.87 4.6 9.89    
0.45 1.21 2.93 4.23 10.2    
0.52 1.22 2.88 4.1 10.32    
0.52 1.14 2.97 4.33 10.22    
0.50 0.97 3.02      
 
 
03/04/2017 
0.48 222.42* 8126.55* <0.0* 10.05 42.41 88.67 328.64 
0.52 1.03 <0.0* 4.33 9.66 42.64 89.93 327.79 
0.45 1.05 932.03* 4.24 9.48 43.60 86.48 326.02 
0.51 1.20 <0.0* 4.12 10.12 45.19 88.01 2287.22* 
0.49 217.72* <0.0* 4.29 8.72 44.22 88.65 336.14 
 
 
04/04/2017 
(am) 
0.40 1.15 2.75 4.11 9.41 44.35 90.28 331.09 
0.39 1.20 2.80 3.91 10.31 45.02 90.29 331.04 
0.57 1.15 2.93 6.56* 9.98 45.77 85.77 331.35 
0.52 1.26 2.88 4.15 9.57 45.48 88.60 322.33 
0.51 1.02 2.93 4.30 8.51 46.38 90.77 332.40 
 
 
05/04/2017 
(am) 
0.53 1.26 2.51 4.22 <0.00* 43.88 91.76 327.12 
0.37 1.25 2.80 3.88 <0.00* 46.12 92.14 329.78 
0.54 1.25 2.94 4.29 <0.00* 46.37 82.06 338.29 
<0.00* 1.15 2.95 4.35 <0.00* 46.35 85.39 324.50 
0.46 1.30 2.92 4.25 9.38 47.38 87.94 323.05 
 
 
05/04/2017 
(pm) 
0.44 <0.00* 2.83 4.58 10.05 43.12 89.67 319.18 
0.60 <0.00* 2.81 4.41 10.11 45.13 90.85 336.07 
0.62 <0.00* 2.73 4.59 10.39 44.63 87.69 328.50 
0.54 1.09 2.82 4.26 9.90 45.11 86.83 326.29 
<0.00* 1.09 3.13 4.51 9.77 51.27 89.64 334.71 
 
 
06/04/2017 
0.47 1.31 3.15 4.60 10.92 46.99   
0.57 1.41 2.64 4.76 9.31 45.17   
 1.40 2.87 4.66 9.55 47.45   
 1.32 3.00  9.91 46.36   
 1.34 3.18  9.69 45.53   
 
 
11/01/2017 
      82.82 333.05 
      89.11 338.66 
      90.59 343.23 
      91.42 311.71 
      91.76 324.74 
 
 
12/04/2017 
       337.96 
       335.23 
       330.98 
       345.65 
       302.75 
 
 
13/04/2017 
(am) 
0.51 1.08  4.36 9.43    
0.51 1.36  4.69 9.68    
0.47 1.19  4.53 10.12    
0.52 1.27  4.66 9.93    
0.50 1.28  3.81 9.84    
 
 
13/04/2017 
(pm) 
0.49   4.31     
0.44   4.73     
0.52   4.47     
0.50   4.72     
0.51   4.09     
 
 
18/04/2017 
   4.66     
   4.45     
   4.72     
   4.74     
   4.78     
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Mean 0.50 1.20 2.89 4.39 9.81 45.36 88.68 329.59 
SD 0.05 0.11 0.15 0.26 0.48 1.87 2.64 8.81 
Count 35 30 25 40 30 25 25 29 
CV(%) 10.68 9.45 5.19 5.91 4.92 4.12 2.98 2.67 
 
 
Table VII. First twenty five results of the Singulex QC, across different days. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control level 2 (ng/L) 
Date Rep 1 Rep 2 Mean 
14/03/2017 26.97 28.10 27.54 
15/03/2017 28.90 29.45 29.18 
16/03/2017 26.91 27.65 27.28 
17/03/2017 28.10 29.86 28.98 
20/03/2017 27.52 27.79 27.66 
21/03/2017 30.12 29.08 29.60 
22/03/2017 29.02 28.76 28.89 
28/03/2017 27.49 29.08 28.29 
30/03/2017 27.22 27.22 27.22 
03/04/2017 26.55 28.11 27.33 
04/04/2017 28.34 28.45 28.40 
05/04/2017 27.73 28.19 27.96 
06/04/2017 29.69  29.69 
 
Mean 28.25  28.31 
SD 0.97 0.89 
Count 25 13 
CV(%) 3.45 3.14 
+ 2SD 30.20 30.08 
-2SD 26.30 26.53 
Control level 1 (ng/L) 
Date Rep 1 Rep 2 Mean 
14/03/2017 8.68 9.36 9.02 
15/03/2017 9.48 9.85 9.67 
16/03/2017 8.68 8.62 8.65 
17/03/2017 9.28 9.17 9.23 
20/03/2017 8.97 8.84 8.91 
21/03/2017 9.17 9.94 9.56 
22/03/2017 9.84 10.24 10.01 
28/03/2017 9.03 9.92 9.48 
30/03/2017 8.76 8.95 8.86 
03/04/2017 9.36 10.36 9.86 
04/04/2017 9.52 9.59 9.56 
05/04/2017 9.25 9.12 9.19 
06/04/2017 9.74  9.74 
 
Mean 9.35  9.36 
SD 0.49 0.43 
Count 25 13 
CV(%) 5.26 4.54 
+ 2SD 10.33 10.21 
-2SD 8.36 8.51 
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Only samples highlighted in green were used for precision calculations, even if they 
were not tested in the same day, together with pools with different concentration.  
The compilations of the results for each different concentrated pool are shown in 
Table VIII. These results include all the different pools, the mean for each pool, SD and 
CV in a count of 25 runs per each pool, in one run per day with five replicates per run. 
The results for CV and CI are shown on Table IX. 
 
 
 
 
 
 
 
 
 
Control level 3 (ng/L) 
Date Rep 1 Rep 2 Mean 
14/03/2017 65.58 65.77 65.68 
15/03/2017 68.02 67.91 67.97 
16/03/2017 64.07 62.97 63.52 
17/03/2017  67.18 66.51 66.85 
20/03/2017  69.87 65.94 67.91 
21/03/2017  69.37 68.86 69.12 
22/03/2017  68.25 68.47 68.36 
28/03/2017  68.14 70.34 69.24 
30/03/2017 64.71 64.11 64.41 
03/04/2017 68.27 69.46 68.87 
04/04/2017 67.45 68.36 67.91 
05/04/2017 68.27 73.03 70.65 
06/04/2017 71.20  71.20 
 
Mean 67.68  67.82 
SD 2.35 2.24 
Count 25 13 
CV(%) 3.47 3.30 
+ 2SD 72.38 72.30 
     -2SD 32.99 63.34 
Control level 4 (ng/L) 
Date Rep 1 Rep 2 Mean 
14/03/2017 14518.13 14614.15 14566.14 
15/03/2017 14444.44 14292.14 14368.29 
16/03/2017 14395.82 14371.37 14383.60 
17/03/2017 14439.33 14273.05 14356.19 
20/03/2017 15576.97 15173.69 15375.33 
21/03/2017 14767.55 14804.32 14785.94 
22/03/2017 14513.00 14568.00 14540.50 
28/03/2017 14762.00 15432.00 15097.00 
30/03/2017 15035.80 14771.71 14903.76 
03/04/2017 15336.81 15515.73 15426.27 
04/04/2017 15766.22 15856.64 15811.43 
05/04/2017 15530.02 14931.20 15230.61 
06/04/2017 15024.88  15024.88 
 
Mean 489.36  14913.07 
SD 489.36 464.93 
Count 25 13 
CV(%) 3.28 3.12 
+ 2SD 15887.32 15842.93 
     -2SD 13929.87 13983.21 
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Table VIII. Compilations of the results concentrations, mean, SD, CV (%) and count for each different 
concentrated pool testes in the Sgx Clarity System. 
 Pools (ng/L) 
0.5 1.25 3 5 10 50 100 300 
0.51 1.19 2.87 4.22 10.05 42.41 88.67 331.09 
0.45 1.21 2.93 3.88 9.66 42.64 89.93 331.04 
0.52 1.22 2.88 4.29 9.48 43.60 86.48 331.35 
0.52 1.14 2.97 4.35 10.12 45.19 88.01 322.33 
0.50 0.97 3.02 4.25 8.72 44.22 88.65 332.40 
0.48 1.15 2.75 4.58 9.41 44.35 90.28 327.12 
0.52 1.20 2.80 4.41 10.31 45.02 90.29 329.78 
0.45 1.15 2.93 4.59 9.98 45.77 85.77 338.29 
0.51 1.26 2.88 4.26 9.57 45.48 88.60 324.50 
0.49 1.02 2.93 4.51 8.51 46.38 90.77 323.05 
0.40 1.26  2.51 4.36 10.05 43.88 91.76 319.08 
0.39 1.25  2.80 4.69 10.11 46.12 92.14 336.07 
0.57 1.25 2.94 4.53 10.39 46.37 82.06 328.50 
0.52 1.15 2.95 4.66 9.90 46.35 85.39 326.29 
0.51 1.30 2.92 3.81 9.77 47.38 87.94 334.71 
0.51 1.31 2.83 4.31 10.92 43.12 89.67 33.05 
0.51 1.41 2.81 4.73 9.31 45.13 90.85 338.66 
0.47 1.40 2.73 4.47 9.55 44.63 87.69 343.23 
0.52 1.32 2.82 4.72 9.91 45.11 86.83 311.71 
0.50 1.34 3.13 4.09 9.69 51.27 89.64 342.74 
0.49 1.08 3.15 4.66 9.43 46.99 82.82 337.96 
0.44 1.36 2.64 4.45 9.68 45.17 89.11 335.23 
0.52 1.19 2.87 4.72 10.12 47.45 90.59 330.98 
0.50 1.27 3.00 4.74 9.93 46.36 91.42 345.65 
0.51 1.28 3.18 4.78 9.84 46.36 91.76 302.75 
  
Mean 0.49 1.23 2.89 4.44 9.78 45.36 88.68 329.59 
SD 0.04 0.11 0.15 0.26 0.50 1.87 2.64 2.85 
CV 8.15 8.84 5.19 5.93 5.10 4.12 2.98 2.85 
Count 25 25 25 25 25 25 25 25 
 
Table IX. Mean, CV and CI of total and repeatability pools. 
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With all the results and focused on Singulex cTnI intermediate precision some 
precision profile figures were made.  They compare the concentration (ng/L) with the CV 
(%) (Figures 12-15). 
 
 
 
 
 
 
 
 
 
 
Figure 12. Comparison between the concentration (ng/L) and the CV (%) showing a precision profile for a 
range of 0-300 ng/L. 
 
    
 
 
 
 
 
 
 
 
 
Figure 13. Comparison between the concentration (ng/L) and the CV (%) showing a precision profile for a 
range of 0-50ng/L. 
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Figure 14. Comparison between the concentration (ng/L) and the CV (%) showing a precision profile for a 
range of 0-10ng/L. 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Comparison between the concentration (ng/L) and the CV (%) showing a precision profile of a 
range of 0-4.5ng/L. 
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3.2.2. Roche intermediate precision data 
 
         All the pools tested on Sgx Clarity System were also tested on Cobas 8000 cTnT 
assay. The compilations of the results for each different concentrated pool are shown in 
Table X. These results include all the different pools, the mean for each pool, SD and CV 
in a count of 25 runs per each pool, in one run per day with five replicates per run. CV and 
CI were also calculated and are shown on Table XI. 
 
Table X. Compilations of the results concentrations, mean, SD, CV (%) and count for each different 
concentrated pool testes in the Cobas 8000. 
  Pools (ng/L) 
Repeat 5 10 50 100 300 
 
03/04/2017 
1 5.70 43.87 39.07 65.32 169.20 
2 5.74 44.21 38.65 65.69 171.20 
3 5.63 44.44 38.91 66.17 171.30 
4 5.40 43.88 38.63 66.28 168.60 
5 5.64 43.64 39.32 65.75 170.90 
 
04/04/2017 
(am) 
6 5.50 45.14 39.04 65.89 168.70 
7 5.24 44.93 38.96 66.73 169.40 
8 5.43 44.37 39.58 65.85 170.90 
9 5.78 44.20 39.36 66.62 166.90 
10 5.31 42.95 39.46 66.82 170.10 
 
04/04/2017 
(pm) 
11 5.24 44.03 38.83 66.21 168.50 
12 5.54 43.55 39.77 65.90 169.60 
13 5.39 44.47 39.57 66.58 169.80 
14 5.67 44.20 38.06 65.84 173.00 
15 5.94 44.51 38.65 66.85 169.10 
 
05/04/2017 
(am) 
16 5.73 45.85 41.42 69.26 178.30 
17 5.18 46.05 40.31 68.73 177.80 
18 4.84 46.46 39.91 68.95 177.40 
19 5.45 46.47 39.95 68.95 180.50 
20 5.70 45.94 40.00 69.95 177.10 
 
05/04/2017 
(pm) 
21 5.14 46.33 40.99 69.63 179.50 
22 5.47 45.49 41.21 70.41 179.50 
23 5.07 46.02 40.98 69.01 179.10 
24 4.98 45.56 41.22 69.66 178.80 
25 5.15 46.64 40.64 69.86 179.60 
  
Mean 5.43 44.93 39.70 67.48 173.39 
SD 0.28 1.07 0.95 1.71 4.66 
Count 25 25 25 25 25 
CV (%) 5.14 2.39 2.38 2.53 2.69 
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n 25
Runs per day 1
Replicates per run 5
Total Repeatability 
Coded Concentration Days Mean CV 95% CI CV 95% CI
5.4344 5 5.434 5.2% 4.0% to 7.8% 4.6% 3.5% to 6.6%
39.6996 5 39.700 2.6% 1.6% to 5.6% 1.2% 0.9% to 1.7%
44.928 5 44.928 2.6% 1.7% to 5.7% 1.1% 0.9% to 1.6%
67.4764 5 67.476 2.8% 1.7% to 7.9% 0.7% 0.5% to 1.0%
173.392 5 173.392 2.9% 1.8% to 8.4% 0.8% 0.6% to 1.1%
Table XI. Mean, CV and CI of total and repeatability pools. 
 
 
 
 
 
With all the results and focused on Roche cTnT intermediate precision some profile 
figure was made. In the Figure 16 all the different concentration (ng/L), representative of 
mean, are compared with the CV (%). 
 
 
Figure 16. Comparison between all the different concentration (ng/L) and the CV (%). 
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performed on the Sgx Clarity System.  
The results for the different pools and Singulex QCs are shown on Table XII in an 
increscent order from the lowest to the higher concentration. The mean, SD, count and CV 
are also showing in the same table as well as the days were the samples were tested.  
0
2
4
6
8
10
12
14
16
0 20 40 60 80 100 120 140 160 180
C
V
 (
%
) 
Concentration (ng/L) (mean) 
Precision Profile 
T
ot
al
 46 
 
 
Table XII. Results of the concentration, mean, SD, count and CV (%) of the pools and the Singulex QCs 
tested on Sgx Clarity System. The results are show in an increased concentration order. 
Sample 0.5 pool 
(ng/L) 
1.25 pool 
(ng/L) 
3.0 pool 
(ng/L) 
5.0 pool 
(ng/L) 
Singulex 1 
(ng/L) 
10.0 pool 
(ng/L) 
1 0.51 0.98 2.45 4.36 9.35 9.43 
2 0.51 1.03 2.60 4.69 9.49 9.68 
3 0.47 1.16 2.72 4.53 9.38 10.12 
4 0.52 1.04 2.76 4.66 9.61 9.93 
5 0.50 1.20 2.88 3.81 10.14 9.84 
6 0.50 1.24 2.91 4.23 10.51 9.95 
7 0.52 1.20 2.70 4.12 10.50 10.13 
8 0.54 1.12 2.92 4.40 10.52 10.38 
9 0.50 1.03 2.40 4.65 10.24 8.89 
10 0.51 1.08 2.59 4.44 10.39 9.67 
11 0.47 1.11 3.00 4.45 10.69 10.16 
12 0.50 1.16 2.91 4.61 10.83 9.28 
13 0.48 1.09 2.63 3.96 10.00 9.36 
14 0.49 1.24 2.83 4.33 9.98 10.30 
15 0.51 1.23 2.79 4.34 10.43 10.47 
16 0.48 1.18 3.06 4.50 9.01 10.28 
17 0.56 1.24 2.83 4.46 9.16 10.59 
18 0.47 1.22 3.00 4.25 9.28 10.09 
19 0.52 1.31 2.17 4.44 9.01 11.70 
20 0.52 1.06 2.75 4.66 9.60 9.12 
Date 13/04/2017 13/04/2017 13/04/2017 13/04/2017 13/04/2017 13/04/2017 
Mean 0.50 1.15 2.75 4.40 9.91 9.97 
SD 0.02 0.09 0.22 0.23 0.60 0.62 
Count 20 20 20 20 20 20 
CV (%) 4.66 7.90 8.13 5.31 6.02 6.23 
 
Sample Singulex 2 
(ng/L) 
50.0 pool 
(ng/L) 
Singulex 3 
(ng/L) 
100 pool 
(ng/L) 
300 pool 
(ng/L) 
Singulex 4 
(ng/L) 
1 26.35 47.53 66.13 88.34 337.96 14097.06 
2 27.70 47.55 67.16 87.18 335.23 16054.25 
3 27.97 47.29 67.75 91.39 330.98 16191.86 
4 28.71 46.57 71.09 91.05 345.65 15781.40 
5 28.42 45.21 63.38 91.05 302.75 16604.41 
6 29.11 45.08 62.65 92.05 317.29 15819.05 
7 28.69 48.15 66.98 89.37 322.42 15709.00 
8 29.93 49.10 67.10 94.23 334.07 16111.17 
9 27.50 46.97 67.92 79.66 332.81 14644.14 
10 26.39 49.37 68.79 95.91 324.81 15201.57 
11 27.61 47.87 66.52 93.50 335.63 15480.57 
12 27.73 48.95 68.87 88.49 331.65 16111.09 
13 28.92 44.70 58.44 90.58 322.37 15587.98 
 47 
 
14 29.19 47.06 59.03 90.61 321.04 15292.67 
15 28.30 47.26 62.71 92.44 328.99 15862.73 
16 28.38 47.81 66.33 94.11 324.80 15464.75 
17 25.58 48.41 65.23 94.32 343.47 15543.54 
18 26.71 48.32 64.57 94.20 326.41 15570.35 
19 28.15 48.19 68.34 92.44 365.00 15386.91 
20 27.81 47.49 65.38 85.23 334.55 14347.66 
Date 12/04/2017 12/04/2017 12/04/2017 12/04/2017 12/04/2017 12/04/2017 
Mean 27.96 47.44 65.72 90.31 330.89 15543.11 
SD 1.08 1.28 3.20 3.71 12.51 618.20 
Count 20 20 20 20 20 20 
CV (%) 3.85 2.70 4.86 4.11 3.78 3.98 
 
 
 
 
 
3.3. Linearity study  
As part of linearity study two pools with a concentration of 350 ng/L and 25ng/L were 
diluted with a base pool separately in triplicate to give the following dilutions: neat, 80%, 
60%, 40%, 20%, 15%, 10% and 5% in a final volume of 400µL. The triplicate dilutions 
were measured on Sgx System Clarity and the results for the concentration of the 
successive dilutions are show on Table XIII and XIV, for the 350ng/L pool and 25ng/L 
pool, respectively. The same tables include the volume of the pool concentrated and the 
volume of the base pool used to get the % required.  
 
Table XIII. Volume of the pool concentrated and of the base pool used, as well as the concentration of the 
diluted pools from the main pool with a concentration of 350ng/L. 
Sample 350 pool (µL) Diluent (µL) Concentration 
100% 400 0 350 
80% 320 80 280 
60% 240 160 210 
40% 160 240 140 
20% 80 320 70 
15% 60 340 52.5 
10% 40 360 35 
5% 20 380 17.5 
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Table XIV. Volume of the pool concentrated and of the base pool used, as well as the concentration of the 
diluted pools from the main pool with a concentration of 25ng/L. 
Sample 27 pool (µL) Diluent (µL) Concentration 
100% 400 0 27 
80% 320 80 21.6 
60% 240 160 16.2 
40% 160 240 10.8 
20% 80 320 5.4 
15% 60 340 4.05 
10% 40 360 2.7 
5% 20 380 1.35 
 
 
 
With all the results and focused on Singulex cTnI linearity study some profile 
figures were made.  In this figures the different dilution (%) were compared with the 
concentration results (ng/L). The results shown on Figure 17 and Figure 18 are related to 
pool with a concentration of 350ng/L and 25ng/L, respectively.   
 
 
Figure 17. Comparison between the different dilutions with concentrations results of the diluted pools from 
the main pool with a concentration of 350ng/L. 
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3.4. Patient comparison study  
In order to compare the results from Singulex cTnI assay with a cTnI assay from a 
different company, and with a cTnT assay, some spare excess serum was collected from 
sixty anonymised patients’ samples that had been run on the Abbot Architect STAT HS 
Troponin I assay.  
In the same day all sixty samples were processed on Sgx Clarity System and Cobas 
8000 from Roche. The concentrations results for all 60 samples tested on the three 
different analysers (Abbot Architect, Sgx Clarity System and Cobas 8000) are shown on 
Table XV. 
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Figure 18.Comparison between the different dilutions with concentrations results of the diluted pools from the 
main pool with a concentration of 25 ng/L. 
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Table XV. Concentration results for the same patient testes in Abbot Architect cTnI assay, Sgx Clarity 
System cTnI assay and Roche cTnT assay. 
Sample number Architect cTnI (ng/L) Singulex cTnI (ng/L) Roche cTnT (ng/L) 
1 9 5.59 7.96 
2 20 9.51 54.37 
3 71 57.54 101.00 
4 230 91.82 11160 
5 72 5.6 19.83 
6 28 10.19 30.19 
7 <2* 1.52 <3* 
8 4 1.72 17.84 
9 100 19.74 67.53 
10 76 28.32 168.80 
11 13 9.26 14.66 
12 4 2.55 25.47 
13 2 1.89 <3* 
14 95 52.64 56.91 
15 30 13.02 35.23 
16 <2* 0.35 <3* 
17 112 12.59 10.32 
18 5 2.51 17.98 
19 30 24.38 43.59 
20 17 6.68 26.41 
21 9 4.47 5.54 
22 88 117.23 26.11 
23 <2* 1.44 6.96 
24 28 15.64 42.65 
25 7 3.59 5.12 
26 24 11.91 29.86 
27 67 49.58 58.24 
28 50 9.29 20.91 
29 10 4.59 13.73 
30 4 3.28 4.300 
31 106 110.82 32.32 
32 85 60.37 51.02 
33 52 8.51 21.53 
34 4 2.99 4.01 
35 4 2.86 4.09 
36 3 2.30 <3* 
37 3 2.06 12.45 
38 3 1.37 <3* 
39 57 30.02 23.47 
40 <2* 0.93 <3* 
41 50 23.22 60.95 
42 27 14.11 28.94 
43 14 8.96 8.94 
44 10 7.20 7.92 
45 2 1.54 <3* 
46 25 17.52 16.44 
47 <2* 1.17 <3* 
48 3 2.30 11.18 
49 5 3.08 10.06 
50 9 6.49 28.40 
51 <2* 0.78 <3* 
52 6 3.88 7.01 
53 2 2.69 9.29 
54 <2* 0.92 <3* 
55 6 4.00 7.17 
56 <2* 1.77 4.54 
57 10 7.56 36.41 
58 7 11.81 35.76 
59 50 16.62 58.32 
60 <2* 0.92 <3* 
* Samples excluded from the calculations.  
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3.4.1. Abbot Architect HS cTnI Vs Singulex HS cTnI  
 
From all 60 samples tested a total of 51 samples were used in the analysis, 9 
samples could not be included once they did not have an absolute value i.e. <2 ng/L. 
Samples ranged from 2 to 230ng/L for the Architect cTnI method were used to the 
analysis.  Figure 19 shows the compilation between the same samples tested on 
Architect and Singulex.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Compilation between the concentrations of the same samples tested on Architect and Singulex. 
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 In order to compare both analysers and found the bias between them a figure was 
constructed. Figure 20 shows the relation between the differences from Singulex 
concentration to Abbot Architect concentration dividing by the mean of all the samples 
related to the mean of all the samples tested. Therefore, the figure shows the mean 
percentage of difference between the Singulex and Abbot with a result of – 54.5%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Mean percentage difference between the Abbot Architect and the Singulex. 
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 Moreover, the mean absolute of the difference between the Singulex and Abbot was 
calculated and shown on Figure 21. The figure shows the relation between the 
differences from Singulex concentration to Abbot Architect concentration related to the 
mean of all the samples tested. In this figure the result for the mean was -16.1 ng/L. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. Mean absolute difference between the Abbot Architect and the Singulex. 
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3.4.2. Roche HS cTnT Vs Singulex HS cTnI 
 
 
From all 60 samples tested a total of 49 samples were used in the analysis, 11 
samples could not be included since they did not have an absolute value i.e. <3.00 
ng/L. Samples ranged from 41.0 to 168.8ng/L for the Roche cTnT method were used to 
the analysis.  Figure 22 shows the compilation between the same samples tested on 
Roche and Singulex.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Compilation between the concentrations of the same samples tested on Roche and Singulex. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scatter Plot with Passing & Bablok Fit
0
20
40
60
80
100
120
140
160
180
0 50 100 150
Roche cTnT (ng/L)
S
in
g
u
le
X
 c
T
n
I 
(n
g
/L
) Identity
Passing & Bablok (I) f it
(-0.61 + 0.47x)
95% CI bands
 55 
 
 Figure 23 displays the relation between the different from Singulex concentration to 
Roche concentration dividing by the mean of all the samples related to the mean of all the 
samples tested. Therefore, the figure shows the mean percentage of difference between the 
Singulex and Roche with a result of – 66.8%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. Mean percentage difference between the Roche and the Singulex. 
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In addition, the mean absolute of the difference between the Singulex and Roche 
was calculated and shown on Figure 24. The figure shows the relation between the 
differences from Singulex concentration to Roche concentration related to the mean of all 
the samples tested. In this figure the result for the mean was -11.8 ng/L. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Mean absolute difference between the Roche and the Singulex. 
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3.4.3. Roche HS cTnT Vs Abbot Architect HS cTnI 
 
 
From among of all 60 samples tested a total of 47 samples were used in the 
analysis, 13 samples could not be included because they did not have an absolute value 
i.e. <2.00 ng/L or <3.00 ng/L in Abbott Architect and Roche, respectively. Samples 
range from 41.0 to 168.8ng/L for the Roche cTnT method were used to the analysis.  
Figure 25 shows the compilation between the same samples tested on Roche and 
Architect.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. Compilation between the concentrations of the same samples tested on Roche and Architect. 
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Figure 26 shows the relation between the different from Abbott Architect 
concentration to Roche concentration dividing by the mean of all the samples related to 
the mean of all the samples tested. Also, the figure shows the bias of the relation 
between the Abbott Architect and Rochet with a result of – 10.87%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. Mean percentage difference between the Roche and the Abbot Architect. 
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Additionally, the mean absolute of the difference between the Abbott Architect and 
Roche was calculated and shown on Figure 27. The figure shows the relation between the 
different from Abbot Architect concentration to Roche concentration related to the mean of 
all the samples tested. In this figure the result for the mean was 5.3 ng/L. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27. Mean absolute difference between the Roche and the Abbot Architect. 
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Table XVI. Concentration results for the pool no 1 stored at room temperature, 4ºC and -20 ºC for the five 
subsequent days and the corresponding mean. 
 pool no 1, rom temp pool no 1, 4ºC pool no 1, -20ºC 
Day 0 1 2 3 4 0 1 2 3 4 0 1 2 3 4 
 0.92 0.75 0.60 0.59 0.64 0.92 0.83 0.62 0.65 0.68 0.92 0.94 1.00 0.88 0.87 
0.98 0.73 0.56 0.60 0.51 0.98 0.84 0.72 0.54 0.50 0.98 1.01 0.92 0.97 0.82 
Mean 0.95 0.74 0.58 0.60 0.58 0.95 0.84 0.67 0.60 0.59 0.95 0.98 0.96 0.93 0.85 
 
 
Table XVII. Concentration results for the pool no 2 stored at room temperature, 4ºC and -20 ºC for the five 
subsequent days and the corresponding mean. 
 pool no 2, rom temp pool no 2, 4ºC pool no 2, -20ºC 
Day 0 1 2 3 4 0 1 2 3 4 0 1 2 3 4 
 1.57  1.22 0.97 1.00 1.13 1.57 1.52 1.22 1.17 1.02 1.57 1.32 1.58 1.33 1.28 
1.59 1.32 1.04 1.04 0.86 1.59 1.34 1.14 1.05 0.99 1.59 1.37 1.47 1.45 1.43 
Mean 1.58 1.27 1.01 1.02 1.00 1.58 1.43 1.18 1.11 1.01 1.58 1.35 1.53 1.39 1.36 
 
 
Table XVIII. Concentration results for the pool no 3 stored at room temperature, 4ºC and -20 ºC for the five 
subsequent days and the corresponding mean. 
 pool no 3, rom temp pool no 3, 4ºC pool no 3, -20ºC 
Day 0 1 2 3 4 0 1 2 3 4 0 1 2 3 4 
 3.16 2.73 2.36 2.47 1.86 3.16 3.14 2.60 2.82 2.41 3.16 2.23 2.97 3.07 2.86 
2.93 3.00 2.33 2.41 2.05 2.93 3.13 2.60 2.68 2.52 2.93 3.14 3.03 3.21 3.32 
Mean 3.05 2.87 2.35 2.44 1.96 3.05 3.14 2.60 2.75 2.47 3.05 3.19 3.00 3.14 3.09 
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Table XIX. Concentration results for the pool no 4 stored at room temperature, 4ºC and -20 ºC for the five 
subsequent days and the corresponding mean. 
 pool no 4, rom temp pool no 4, 4ºC pool no 4, -20ºC 
Day 0 1 2 3 4 0 1 2 3 4 0 1 2 3 4 
 83.04 77.62 78.37 69.70 63.08 83.04 72.58 71.51 65.22 71.34 83.04 83.77 83.21 82.32 80.84 
75.83 80.48 73.80 69.05 64.90 75.83 75.79 74.47 68.54 71.50 75.83 84.51 83.71 85.25 77.99 
Mean 79.44 79.05 76.09 69.38 63.99 79.44 74.19 72.99 66.88 71.42 79.44 84.14 83.46 83.79 79.42 
 
 
 
 
 
Table XX. Concentration results for the pool no 5 stored at room temperature, 4ºC and -20 ºC for the five 
subsequent days and the corresponding mean. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 pool no 5, rom temp pool no 5, 4ºC pool no 5, -20ºC 
Day 0 1 2 3 4 0 1 2 3 4 0 1 2 3 4 
 314.30  263.51 227.82 227.23 244.37 314.30 282.86 275.82 258.02 257.33 314.30 320.37 320.77 281.68 310.17 
334.92 280.84 242.80 244.98 244.53 334.92 296.14 295.62 268.20 234.07 334.92 322.70 320.51 290.86 301.98 
Mean 324.61 272.18 235.31 236.11 244.45 324.61 289.50 285.72 263.11 245.70 324.61 321.54 320.64 286.27 306.18 
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With all the results and focused on Singulex cTnI stability study some profile 
figures were made.  In this figures (28, 29, 30, 31 and 32) the concentration of each pool, 
affected by temperature and time, were compared with the subsequent days where the pool 
were tested.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28. Variation of the concentration of pool no 1, stored at different temperatures, within five days. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29. Variation of the concentration of pool no 2, stored at different temperatures, within five days. 
 63 
 
0,00
0,50
1,00
1,50
2,00
2,50
3,00
3,50
Day 0 Day 1 Day 2 Day 3 Day 4
50 ng/L RT
50 ng/L 4C
50 ng/L 20C
0,00
10,00
20,00
30,00
40,00
50,00
60,00
70,00
80,00
90,00
Day 0 Day 1 Day 2 Day 3 Day 4
100 ng/L RT
100 ng/L 4C
100 ng/L 20C
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30. Variation of the concentration of pool no 3, stored at different temperatures, within five days. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31. Variation of the concentration of pool no 4, stored at different temperatures, within five days. 
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Figure 32. Variation of the concentration of pool no 5, stored at different temperatures, within five days. 
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4.1  Discussion  
Specifications of a perfect cardiac biomarker to diagnose AMI include as a minimum, 
cardiac specificity, early detection after first symptoms and a long half-life. The presence 
of an elevation of circulating cTn, the current preferred biomarkers to diagnose AMI, is 
indicative of myocardial injury. It has been shown that there is a consistently strong direct 
relationship between increased cTn concentration and the risk of short- and long-term 
cardiac events and mortality in patients who present with symptoms of ACS in the ED. The 
main advantage of cTn is its cardiac specificity and its timeframe of release. 
(15,53,59,60)
 
High-sensitivity cardiac troponin assay have recently emerged enabling reliable 
measurement of cTn values in healthy individuals. These assays allow measurement of 
even low cTn concentrations with high precision, and have been shown to provide high 
diagnostic accuracy for AMI already at presentation. 
(47,61)
 
The ability to rapidly and accurately diagnose patients with symptoms of chest pain to 
the ED is of critical importance because of the short-term mortality for patients with MI 
who are mistakenly discharged from the hospital. In addition, diagnostic uncertainty may 
delay initiation of definitive treatment of patients. Even for the physician within the ED 
who wants a precise assay at the 99
th
 percentile cutoff, there is an interest that undetectable 
and/or low hs-cTn result may identify patients at low risk of ACS and possibly suitable for 
early discharge.
(30,58,62) 
 
With the development of more sensitive and precise hs-cTn assays, and their ability to 
determine small differences in cTn over time, new possibilities become available to 
improve risk stratification and to facilitate the identification of patients at risk for a 
cardiovascular event. The present study undertook an analytical validation of a novel high 
sensitivity assay to determine if the performance characteristics and laboratory usability 
would allow it to perform in such a role.  
 
4.1.1. Percent normal study  
 
 
In the present study hs cTnI was measured in a large, presumed, healthy population. 
Our results demonstrated that the Singulex hs-cTnI assay measured 100% of 
concentrations in all healthy subjects, resulting in a concentration range of 0.13-11.27 
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ng/L. Most current cTn assays do not detect cTn in 50% of apparently healthy individuals 
whereas high-sensitivity assays do and with some, detection may be as high as in 90%. 
(55)
 
However, although the population studied was assumed as healthy, it is known that 
increased hs-cTnI or cTnT concentrations can result from other pathological etiologies that 
cause myocardial cell injury, cell death, and release of cTn into the blood. It is therefore 
possible that some of the population studied had subclinical disease. 
(63)
 
According with the literature, our observations also demonstrated a significant 
difference between men and women.  Previous studies reported substantially higher 99
th
 
percentile values in males vs females, using four hs-cTnI assays (Abbott ARCHITECT hs-
cTnI; Beckan hs-cTnI; Siemens Dimension Vista hs-cTnI; Singulex Erenna hs-cTnI). 
Moreover, previous studies have shown a sex difference for the hs-cTnT assay. 
(15,44,64)
 
Ischemic heart disease is more common in males, but the population studied was 
presumed to be healthy. So the explanation may be that as male hearts are on average 
larger than female hearts, a sex difference in distribution of troponin values would be 
expected. 
(15)
 
The observations in the present study also demonstrated an association between the 
values for cTnI and age of the healthy individuals, with values tending to increase with 
age.  The project based on the Biomarkers for Cardiovascular Risk Assessment in Europe 
(BiomarCaRe) had suggesting that the addition of troponin I led to a greater incremental 
risk prediction with rising age. 
(64,65)
  
The troponin I concentrations in apparently health subjects are continuously 
associated with fatal cardiovascular events and to a lesser extent with incident 
cardiovascular disease as well as overall mortality. Risk phenotypes such as the degree of 
atherosclerosis, ventricular hypertrophy and vascular stiffness together with very low 
circulating levels of troponin I explain a substantial proportional of cardiovascular risk. 
However, elevated concentration at baseline is most probably due to subclinical cardiac 
pathology which increases the risk of cardiovascular death. Higher troponin concentrations 
may reflect subclinical CAD and identify those at greatest risk who could benefit from 
targeted preventative therapies.  
(64,65)
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4.1.2. Precision study  
 
For the clinical utilization of a high sensitivity assay, very short time intervals 
between sequential sampling was recommended, with samples taken  on admission, 90 
min, 2h and 3h post admission and possibly admission and 1h from admission. In order to 
use such shorter time interval between high-sensitivity cardiac troponin measurements 
safely a high degree of repeatability is required. 
(46,66)
 
Our results from the pools tested on Sgx Clarity System have shown a CV of <10% 
for all the pools, as well as the same pools tested on Cobas 8000, for cTnT. The results 
have shown a lower CV in the high concentrations pools and demonstrate very high 
precision at higher levels of cTnI. On the other hand, the results for the intermediate 
precision pools using Roche cTnT assay are consistent with a previous study using the 
Abbot ARCHITECT hs-cTnI assay, where the hs-cTnI assay has superior precision at 
lower concentrations.
(62)
 
When compared, the results on Sgx Clarity System for hs-cTnI assay and on Cobas 
8000 for hs-cTnT assay the concentrations values were clearly different. In the same pools, 
the concentration of cTnI was larger when compared with cTnT mainly because they are 
different analytes and each have their own biological kinetic characteristics.
(67)  
However, 
consistently with the literature, it is well-known that both troponins I and T levels in 
patients without ACS are at least part linked to renal function. The fact of weight of 
troponin T (37kDa) is bigger than troponin I (22.5kDa) could be an explanation. 
(37,67)
 
For the repeatability precision study, as for the intermediate precision study, all the 
CV represented a value below 10%, representing a high precision and repeatability of the 
assay.  However, because we are using a high sensitivity assay it is important to identify a 
superior precision at low concentrations values, as well as identified at high concentrations 
values.  
With this precision study we concluded that Sgx Clarity System is able to processes 
the same, and different samples, in different times with a high precision. High precision 
and repeatability is critical for the clinical use of the assay, especially when we need to 
compare small changes in concentration of cTn over short time intervals, in order to 
discharge or admit the patient and define the correct treatment for them. 
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4.1.3. Linearity study  
 
In order to test the linearity of the assay, and verify the capacity of the instrument 
of give a direct relation between the results and the concentration of the analyte, in this 
case cTnI, a linearity study was performed.  The assay showed excellent linearity, which 
allows us to conclude that measured changes in value across the assay range will be 
reliable. 
4.1.4. Patient comparison study  
 
Nowadays, comparability testing for hs-cTnI across hospital and laboratories is 
essential because within a city there may be downtime for the analyzers occurring as a 
result of system failure and samples may need to be sent to another site for testing or more 
commonly there will be patients transferred from one hospital to another. A previous study 
indicated that agreement, as assessed by CV, is superior for hs-cTnI as compared to 
cTnI.
(62)
  
Each cTnI assay uses different antibodies, calibrators, control materials, and 
detection techniques, limiting laboratory and multicenter study comparison. 
(15)
 In the 
present study we described and quantified between and within-method differences between 
cTnI assays and between cTnI and cTnT assays. 
Overall, troponin was detectable by the Abbot Architect hs-cTnI assay in 51/60 
samples (85%), by Roche hs-cTnT assay in 49/60 samples (81,7%) and by Singulex hs-
cTnI assay in 60 samples (100%). As mentioned before, in this study Sgx Clarity System 
has detected cTnI concentration in all the samples tested.  
A difference between the results was expected due to the analytical features 
mentioned above as well as factors presented in patient serum, such as anti-cardiac 
troponin antibodies, hemolysis, icterus, lipemia and drugs which may affect individual 
assays differently.
 (33)
 
 
4.1.5. Stability study  
 
In this study all the variables were constant for all samples and all measurements on 
the analyzer were made under similar conditions. Pools with different concentration were 
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stored at different temperatures and tested on the Sgx Clarity System for 5 subsequent 
days.  
The results have shown a time and temperature-dependent degradation in all the 
different serum pools.  
It has to be noticed that stability of cTnI in the pools stored at room temperature 
was lower as compared to those stored at -20ºC, independent of the pools concentration.   
 All the different concentrated pools have shown a decreased in cTnI concentration 
in the pools stored at room temperature, across the 5 subsequent days, when compared with 
those stored at -20ºC, event that there is a decreased of cTnI concentration, the difference 
was not so clear. Another fact is the discrepancy seen in the samples with lower analyte 
concentrations. In the first 3 pools (lowest concentrated pools), the results showed a very 
marked decrease. However in the last two higher concentrated pools the difference was not 
so apparent, which means that samples with higher concentration are more stable when 
stored at -20ºC or even stored at room temperature.  
 In terms of clinical value, this means that high concentrations can be measured after 
sample storage. Hence retrospective confirmation of significant troponin elevation can be 
obtained. However, low concentrations may not be reliably measured if the sample has not 
been stored frozen at -20°.  
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4.2  Conclusion and Future Perspectives 
 
The appropriate use of hs-assays will improve clinical care. In clinical practice hs-
assays will allow the early detection of small cTn changes evolving from low cTn 
concentrations within the reference interval to small increases above the 99
th
 percentile 
value. This will be important in improving the understanding of the role of absolute 
concentration changes and it will improve clinical specificity for MI compared to another 
myocardial injury mechanism.  
Currently, some assays already proposed a very rapid diagnosis. However they need a 
high precision at low levels. Even in the chronic disease detected there is a need of high 
sensitivity to monitor them. Sgx Clarity System is a potential analyzer in an analytical 
performance view. However it doesn’t provide yet the usability necessary for a routine 
laboratory.   
Sgx Clarity System is a batch analyser with capacity for 48 samples per run, however 
in a clinical laboratory where we constantly receive samples we should be able to load 
samples while the others are running. Also, the analytical time is too long and for a routine 
laboratory with a big amount of workload where the turnaround time should be as shorter 
as possible a quick assay is required. Another disadvantage of this instrument is the set up 
time that it is also too long, as well as the calibrators and controls processing time. With all 
this details we concluded that however the instrument is perfectly satisfactory in an 
analytical performance and it is sensitive, measuring small concentrations of cTnI, it is not 
ready to be in a routine laboratory.  
The prospective evaluation of this assay has yet been fully characterized in a larger 
population of patients presenting to the ED with chest pain. As a future research defining 
the diagnostic accuracy it will be interesting to perform a study that includes a delta 
change. A follow-up study is currently underway in our laboratory to examine specimens 
from patients with a diagnosis of MI. 
We note, as a potential limitation, the possibility that with such sensitive limits of 
detection of the assay, low-level nonspecific binding events might contribute to cTnI 
measurements. Also, the presumably healthy study participants used in the percent normal 
study were identified via health conditions and not by clinical using additional screening 
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tools such as imaging, ECG or measurement of a natriuretic peptide, as a surrogate 
myocardial dysfunction biomarker.  
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